Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine

Investors are eyeing a new sector on Wall Street, one that focuses on treating baldness, rather than the popular GLP-1 drugs that have been driving stocks recently. Pattern hair loss affects millions of Americans, both men and women, but there have been no new approved drugs in the field since the 1990s. Companies like Veradermics and Absci have seen their stocks soar in recent months as novel treatments for baldness generate excitement.

Veradermics' stock has nearly quintupled since going public, while Absci's has more than doubled so far this year. Cosmo NV, another player in this space, has also seen positive results for its experimental male hair-loss treatment, though its shares have been impacted by the success of US competitors. For those ineligible for hair transplant surgery or unable to afford it, current options include topical minoxidil or prescription finasteride, both of which can have debilitating side effects.

Analysts see the baldness drug market as an untapped goldmine, reminiscent of the GLP-1 weight-loss drugs that have catapulted companies like Eli Lilly & Co. and Novo Nordisk into the spotlight. One potential treatment, clascoterone, is being developed by Cosmo and could be the "single biggest opportunity" in its portfolio. If approved by the FDA, Cosmo's topical medicine could bring in billions in sales annually.

Analysts predict that multiple drugs could find success in this market, as patients often use a combination of treatments. While drug development is risky, the potential for significant returns makes baldness drugs an attractive prospect for investors.